Arthur Kuan was named President of CG Oncology, Inc. As of November 15, 2026, CG Oncology, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 13, 2026 to May 26, 2026, naming 1 appointment (Form 8-K, May 26, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like CG Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CG Oncology, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-13 to 2026-05-26. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as CG Oncology, Inc. files it.
Also on the record for CG Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by James B. Tananbaum | 4.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RTW Investments, LP | 9.7% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 6% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 8.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 8% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Wellington Management Group LLP | 7.2% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 8.62% of the class | 5%+ stakes | Source |
| October 28, 2025 | Stake report, Schedule 13D/A, by Seven Fleet Capital Management LP | 2% of the class | 5%+ stakes | Source |
| September 18, 2025 | Stake report, Schedule 13D, by Longitude Capital Partners IV, LLC | 6% of the class | 5%+ stakes | Source |
| September 18, 2025 | Stake report, Schedule 13D, by Seven Fleet Partners LP | 2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs CG Oncology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on CG Oncology, Inc. and the records around it.
CG Oncology, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: Lexeo Therapeutics, Inc. (Nov 2025), ZENAS BIOPHARMA, INC. (Oct 2025)
- Seven Fleet Master Fund LP also filed stake reports on 3 other companies: Entera Bio, Ltd. (the "Issuer") (Aug 2026), CytomX Therapeutics, Inc. (May 2026), Veradermics, Inc (May 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: ORCHESTRA BIOMED HOLDINGS, INC. (Nov 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
Watch CG Oncology, Inc.
Get an email when CG Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CG Oncology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CG Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CG Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-26 | In | President | 8-K, 2026-05-26 | ||
| 2026-04-13 | Reported | not named in the filing | 8-K, 2026-04-13 |
Who leads CG Oncology, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Arthur Kuan, appointed (filed 2026-05-26).
New leaders reset buying decisions — get the Full Report on CG Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at CG Oncology, Inc., with the record behind each one.
Find candidates like President at CG Oncology, Inc.Every change, in the filing's words
Appointed: Arthur Kuan, President
Kuan Appointment as President On May 20, 2026, the Company's Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete's separation.
- Bellete Separation On May 20, 2026, CG Oncology, Inc. (the "Company") and Ambaw Bellete, the Company's President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.
- The Company thanks Mr. Bellete for his contributions and wishes him well in his next endeavors.
- The Company has initiated a search for a Chief Commercial Officer.
Reported
On April 13, 2026, CG Oncology, Inc. (the " Company ") appointed Jim DeTore as the Company's Chief Financial Officer.
- Mr. DeTore, age 61, has served as our Interim Principal Financial and Accounting Officer since November 2025 pursuant to a consulting agreement with Monomoy Advisors, LLC, and has been responsible for the Company's financial and accounting functions.
- Prior to joining the Company, from June 2021 to June 2025, Mr. DeTore was Chief Financial Officer at Neurogastrx, Inc. Prior to serving at Neurogastrx, from March 2017 to May 2021, Mr. DeTore was an independent consultant providing chief financial officer services to a variety of early and mid-stage biotechnology and pharmaceutical companies, and from August 2016 to February 2017, Mr. DeTore was with Proteostasis Therapeutics, serving as Chief Financial Officer.
- In addition, from November 2014 to February 2016, Mr. DeTore served as Chief Financial Officer at Bluebird Bio, Inc. Mr. DeTore holds a Bachelor of Science degree and a Master of Business Administration degree from Northeastern University.
- In connection with his appointment as Chief Financial Officer, the Company and Mr. DeTore entered into an employment agreement, dated April 13, 2026 (the "Employment Agreement"), pursuant to which Mr. DeTore will receive an initial annual base salary of $520,000, less applicable withholdings, and will be eligible for an initial annual target bonus of 45% of his annual base salary.
Tools for this story
Each opens in a new tab, filled in for CG Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
